...

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A (vol 129, pg 1245, 2017)

【24h】

Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A (vol 129, pg 1245, 2017)

机译：反对因子VIII的非对抗抗体以及严重血友病的抑制剂发育风险（Vol 129，PG 1245,2017）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2017年第2期|共1页
作者
Cannavo A.; Valsecchi C.; Garagiola I;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A (vol 129, pg 1245, 2017) [J] . Cannavo A., Valsecchi C., Garagiola I Blood: The Journal of the American Society of Hematology . 2017,第2期

机译：反对因子VIII的非对抗抗体以及严重血友病的抑制剂发育风险（Vol 129，PG 1245,2017）
2. Intensity of factor VIII VIII treatment and the development of inhibitors in non‐severe hemophilia A patients: results of the INSIGHT INSIGHT case–control study [J] . Velzen A. S., Eckhardt C. L., Peters M., Journal of thrombosis and haemostasis: JTH . 2017,第7期

机译：因子VIII VIII的强度治疗和非严重血友病患者抑制剂的发展：洞察洞察案例控制研究的结果
3. Polymorphisms in the F8 Gene and MHC-II Variants as Risk Factors for the Development of Inhibitory Anti-Factor VIII Antibodies during the Treatment of Hemophilia A: A Computational Assessment [J] . Gouri Shankar Pandey, Chen Yanover, Tom E. Howard, PLoS Computational Biology . 2013,第5期

机译：F8基因和MHC-II变异中的多态性作为A型血友病治疗过程中抑制性抗因子VIII抗体发展的危险因素：计算评估
4. Inactiwatlon of Animal Factor VIII by human Factor VIII Inhibitors: Inwestigation of Plasma from Patients with Inhibitors in congenital Hemophilia I and from Patients with acquired Hemophilia A [C] . V. Aumann, G. Lutze (Jr.), G. Lutze (Sen.), Hemophilie-Symposion . 2003

机译：人为因子VIII抑制剂的动物因子VIII的乙酰丁酮：先天性血友病药中抑制剂患者的血浆中的预防
5. Satisfaction, Adherence, and Recombinant Factor VIII Choice of Patients with Moderate to Severe Hemophilia A [D] . Strickland, Kimberly. 2020

机译：满意度，依从性和重组因素VIII患者中度至重度血友病的患者
6. Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A [O] . Yohann Repessé, Catherine Costa, Roberta Palla, 2019

机译：内源性血管性假血友病因子的因子VIII结合能力在重度A型血友病患者中因子VIII抑制剂发展中的作用
7. Cannavò A, Valsecchi C, Garagiola I, et al. Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood. 2017;129(10):1245-1250. [O] . 2017

机译：Cannavěa，valsecchi c，garagiola i等。非暴力抗体反对因子VIII和严重血友病A的抑制剂发育风险。 2017; 129（10）：1245-1250。
8. Cooperative Study of Spontaneously-Occurring Factor VIII Inhibitors in Patients with Hemophilia A [R] . Shapiro, S. S. 1981

机译：血友病a患者自发性因子VIII抑制剂的合作研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号